Peptides for Cranial cruciate ligament (CCL) tear in Dogs
The short answer
For cranial cruciate ligament (ccl) tear in dogs, the compounds under investigation are BPC-157, TB-500, MGF — of which BPC-157 has the strongest evidence base, graded emerging. Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs. No compound described here is FDA-approved for this use in dogs, and none should be started without veterinary involvement.
About the condition
The cranial cruciate ligament is the canine equivalent of the human ACL, and its rupture is the most common orthopaedic injury veterinary surgeons see. Unlike in people, canine CCL disease is usually degenerative rather than traumatic — the ligament frays over months before it fails, which is why so many dogs rupture the second side within a year or two. Surgical stabilisation is the standard of care for most dogs. Peptide research in this context is directed at the recovery phase and at the soft tissue environment, not as an alternative to stabilising an unstable joint.
Compounds investigated for this condition
Ranked by strength of the published evidence.
The only peptide on this site with published canine pharmacokinetic data.
BPC-157 is a short chain of fifteen amino acids originally identified in gastric juice. Research describes it encouraging the growth of new blood vessels into damaged tissue, which is the rate-limiting step in most healing. Studies also report a protective effect on the lining of the gut. It is the one compound here with a published pharmacokinetic study performed in dogs, which is why it appears first on almost every canine protocol.
Full BPC-157 profile, dosing and safety →A thymosin beta-4 fragment studied for tissue repair, and well characterised in equine doping-control literature.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Full TB-500 profile, dosing and safety →A locally acting muscle-repair peptide injected near the site of injury.
MGF is a splice variant of the IGF-1 gene that muscle produces in response to mechanical loading and damage. Its half-life is extremely short — around fifteen minutes — which means it acts where it is placed. That is why protocols call for injecting close to the injured muscle rather than anywhere convenient.
Full MGF profile, dosing and safety →Critical safety notes
These apply to the compounds listed above and should be read before considering any of them.
⚠ TB-500: Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
⚠ MGF: Contraindicated with active cancer
As an IGF-1 family growth factor, MGF promotes cell proliferation. It should not be used in a dog with known or suspected malignancy.
Breeds with elevated predisposition
Breed affects both the likelihood of this condition and, in some cases, which compounds are safe.
Labrador Retriever
Carries a breed-specific compound risk
Rottweiler
Cranial cruciate ligament (CCL) tear predisposition
Boxer
Cranial cruciate ligament (CCL) tear predisposition
English Bulldog
Cranial cruciate ligament (CCL) tear predisposition
Newfoundland
Cranial cruciate ligament (CCL) tear predisposition
Common questions
What peptides are used for cranial cruciate ligament (ccl) tear in dogs?+
BPC-157, TB-500, MGF are the compounds investigated for cranial cruciate ligament (ccl) tear in dogs. BPC-157 carries the strongest evidence of these, graded as emerging evidence. None are FDA-approved for this use in dogs.
Do peptides actually help cranial cruciate ligament (ccl) tear in dogs?+
The honest answer is that the canine evidence is limited. Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs. The compounds investigated here have mechanistic support and, in some cases, published animal data — but controlled clinical trials in dogs with cranial cruciate ligament (ccl) tear have not been conducted. Any use is investigational and belongs in a conversation with your veterinarian rather than a decision made independently.
Which breeds are most affected by cranial cruciate ligament (ccl) tear?+
Labrador Retriever, Rottweiler, Boxer, English Bulldog, Newfoundland carry elevated predisposition to cranial cruciate ligament (ccl) tear. Breed matters beyond risk of the condition itself — some breeds carry genetic traits that change which compounds are safe, such as the MDR1 mutation in herding breeds and copper storage disease in Bedlington Terriers and certain Labrador lines.
References
- 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
- 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
- 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
- 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
- 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
- 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
- 12.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
- 13.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.